Activation of TLRs Triggers GLP-1 Secretion in Mice

Int J Mol Sci. 2023 Mar 10;24(6):5333. doi: 10.3390/ijms24065333.

Abstract

The gastrointestinal tract constitutes a large interface with the inner body and is a crucial barrier against gut microbiota and other pathogens. As soon as this barrier is damaged, pathogen-associated molecular patterns (PAMPs) are recognized by immune system receptors, including toll-like receptors (TLRs). Glucagon-like peptide 1 (GLP-1) is an incretin that was originally involved in glucose metabolism and recently shown to be rapidly and strongly induced by luminal lipopolysaccharides (LPS) through TLR4 activation. In order to investigate whether the activation of TLRs other than TLR4 also increases GLP-1 secretion, we used a polymicrobial infection model through cecal ligation puncture (CLP) in wild-type and TLR4-deficient mice. TLR pathways were assessed by intraperitoneal injection of specific TLR agonists in mice. Our results show that CLP induces GLP-1 secretion both in wild-type and TLR4-deficient mice. CLP and TLR agonists increase gut and systemic inflammation. Thus, the activation of different TLRs increases GLP-1 secretion. This study highlights for the first time that, in addition to an increased inflammatory status, CLP and TLR agonists also strongly induce total GLP-1 secretion. Microbial-induced GLP-1 secretion is therefore not only a TLR4/LPS-cascade.

Keywords: cecal ligation puncture; glucagon-like peptide 1; inflammation; polymicrobial infection; toll-like receptors.

MeSH terms

  • Adjuvants, Immunologic
  • Animals
  • Glucagon-Like Peptide 1 / metabolism
  • Lipopolysaccharides*
  • Mice
  • Mice, Inbred C57BL
  • Toll-Like Receptor 4* / metabolism
  • Toll-Like Receptors / metabolism

Substances

  • Toll-Like Receptor 4
  • Lipopolysaccharides
  • Glucagon-Like Peptide 1
  • Toll-Like Receptors
  • Adjuvants, Immunologic

Grants and funding

This research was funded by grants from the Université de Bourgogne, the Institut National de la Santé et de la Recherche Médicale (INSERM), by a French Government grant managed by the French National Research Agency under the program “Investissements d’Avenir” with reference ANR-11 LABX-0021 (Lipstic Labex).